NEUREN PHARMACEUTICALS LIMITED

1.51%

$16.93

Market Cap $2.136B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

Latest Threads

Tag

Subject

NEU

Share Price

272 273 274

20/08/25

16K

8.2M

20/08/25

Last post Little T

16K

8.2M

NEU

Neuren Media and Analyst Coverage

30 31 32

20/08/25

1.8K

1.1M

20/08/25

Last post htae39

1.8K

1.1M

NEU

Katelin’s Turn is HERE!!!

4 5 6

19/08/25

345

221K

19/08/25

Last post Tony barber

345

221K

NEU

PHASE2 PRADER WILLI SYNDROME START !!!!

16/08/25

41K

16/08/25

Last post hottod

41K

NEU

Acadia

26 27 28

15/08/25

1.6K

845K

15/08/25

Last post SergioMarchio

1.6K

845K

NEU

NEU chart

38 39 40

13/08/25

2.3K

1.3M

13/08/25

Last post Taureanbull

2.3K

1.3M

NEU Biotech

The End Game Is Now Clear

13/08/25

30K

13/08/25

Last post Connex

30K

NEU

Ann: Application for quotation of securities - NEU

12/08/25

3.4K

12/08/25

Last post Connex

3.4K

See All Discussions

Timeline

Application for quotation of securities - NEU
12 Aug 16:12	Share

Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline
08 Aug 09:16	Share

DAYBUE Q2 2025 net sales US$96.1 million up 14% from Q2 2024
07 Aug 09:51	Share

Change of Director's Interest Notice - J Pilcher
22 Jul 09:30	Share

Application for quotation of securities - NEU
22 Jul 09:21	Share

Notification regarding unquoted securities - NEU
09 Jul 17:03	Share

Application for quotation of securities - NEU
30 Jun 17:49	Share

US patent allowed for NNZ-2591 to treat Pitt Hopkins
26 Jun 09:25	Share

Notification of cessation of securities - NEU
25 Jun 17:26	Share

Update - Notification of buy-back - NEU
16 Jun 09:28	Share

Update - Notification of buy-back - NEU
16 Jun 09:07	Share

Update - Notification of buy-back - NEU
13 Jun 08:26	Share

Update - Notification of buy-back - NEU
12 Jun 07:45	Share

Update - Notification of buy-back - NEU
11 Jun 08:07	Share

Update - Notification of buy-back - NEU
10 Jun 08:33	Share

Update - Notification of buy-back - NEU
06 Jun 09:13	Share

Update - Notification of buy-back - NEU
05 Jun 07:50	Share

Notification of cessation of securities - NEU
04 Jun 16:30	Share

Update - Notification of buy-back - NEU
04 Jun 08:30	Share

Update - Notification of buy-back - NEU
03 Jun 08:38	Share

Update - Notification of buy-back - NEU
02 Jun 08:51	Share

Update - Notification of buy-back - NEU
30 May 08:41	Share

Update - Notification of buy-back - NEU
29 May 08:00	Share

Update - Notification of buy-back - NEU
28 May 07:31	Share

Results of Meeting
27 May 12:17	Share

AGM Chair Address & CEO Presentation
27 May 10:19	Share

Update - Notification of buy-back - NEU
27 May 08:41	Share

Update - Notification of buy-back - NEU
26 May 09:11	Share

Notification regarding unquoted securities - NEU
23 May 17:15	Share

Approval of long-term equity incentive
23 May 11:51	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $16.93		Change -0.260(1.51%)		Mkt cap ! $2.136B

Open	High	Low	Value	Volume
$17.17	$17.17	$16.67	$5.258M	310.2K

Buyers (Bids)

No.	Vol.	Price($)
1	2547	$16.91

Sellers (Offers)

Price($)	Vol.	No.
$16.93	44	1

View Market Depth

No.	Vol.	Price($)
1	2547	16.910
2	1285	16.900
1	1127	16.890
1	1317	16.870
1	1163	16.850

Price($)	Vol.	No.
16.930	44	1
17.040	2650	2
17.050	3785	3
17.090	1000	1
17.180	350	1

Last trade - 16.10pm 20/08/2025 (20 minute delay)

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED

Latest Threads

Redcastle Resources (ASX:RC1): Strategic JV to Expedite Gold Production & Major Tenement Expansion in Eastern Goldfields

Timeline

Featured News

Latest Videos

Neuren Pharmaceuticals (ASX:NEU) partner drug approved as first treatment for Rett syndrome

13 Mar 2023 10:53 (AEDT)

Neuren Pharmaceuticals (ASX:NEU) receives FDA approval for Prader-Willi syndrome phase II trial

23 Jan 2023 11:16 (AEDT)

Latest Articles

Neuren Pharma jumps on DAYBUE sales win; short sellers' report now history

Dual-listed across the NASDAQ and ASX, Neuren Pharma (ASX:NEU) has jumped +7% down under in the morning Thursday session as...

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Neuren Pharma (ASX:NEU) has seen its shares jump over +11% as the company wins a patent to treat Pitt Hopkins Syndrome...

FDA OK for Neuren's first ever Phase 3 trial in children with Phelan-McDermid syndrome

Neuren has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News